Iterum Therapeutics plc
ITRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $31 | $40 | $42 | $35 |
| - Cash | $11 | $13 | $13 | $24 |
| + Debt | $0 | $33 | $32 | $46 |
| Enterprise Value | $20 | $59 | $61 | $56 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1 | -$0 | $0 |
| % Margin | 94.9% | – | – | – |
| EBITDA | -$8 | -$6 | -$4 | -$5 |
| % Margin | -2,064.4% | – | – | – |
| Net Income | -$9 | -$7 | -$5 | -$7 |
| % Margin | -2,302.3% | – | – | – |
| EPS Diluted | -0.2 | -0.16 | -0.14 | -0.25 |
| % Growth | -25% | -14.3% | 44% | – |
| Operating Cash Flow | -$8 | -$5 | -$3 | -$4 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$8 | -$5 | -$3 | -$4 |